Search research articles
Contact Us
Filters
Showing results (621-630 of 721) with videos related to
Page
of 73
Sort By:
Molecular Cancer Research : MCR
|
January 6, 2023
Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
Claire M Storey, Mohamed Altai, Mesude Bicak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 16, 2017
Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
Jeremie Calais, Wolfgang P Fendler, Matthias Eiber, et al.
Clinical Nuclear Medicine
|
April 16, 2019
Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma
Sied Kebir, Lazaros Lazaridis, Manuel Weber, et al.
European Urology
|
January 7, 2024
Safety Analyses of the Phase 3 VISION Trial of [<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
Kim N Chi, Andrew J Armstrong, Bernd J Krause, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 23, 2024
Prognostic Implications of <sup>68</sup>Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors
Masao Watanabe, Wolfgang P Fendler, Hong Grafe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 11, 2017
<sup>68</sup>Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning
Jeremie Calais, Johannes Czernin, Minsong Cao, et al.
The Lancet. Oncology
|
October 11, 2018
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group
Frédéric E Lecouvet, Daniela E Oprea-Lager, Yan Liu, et al.
Clinical Lung Cancer
|
April 11, 2018
MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy
Henning Reis, Martin Metzenmacher, Moritz Goetz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 14, 2017
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Thomas A Hope, Emily K Bergsland, Murat Fani Bozkurt, et al.
Lancet (London, England)
|
June 8, 2024
[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
Simron Singh, Daniel Halperin, Sten Myrehaug, et al.
Page
of 73
Search research articles
Search
Showing results (621-630 of 721) with videos related to
Sort By:
Page
of 73
Molecular Cancer Research : MCR
|
January 6, 2023
Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
Claire M Storey, Mohamed Altai, Mesude Bicak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 16, 2017
Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
Jeremie Calais, Wolfgang P Fendler, Matthias Eiber, et al.
Clinical Nuclear Medicine
|
April 16, 2019
Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma
Sied Kebir, Lazaros Lazaridis, Manuel Weber, et al.
European Urology
|
January 7, 2024
Safety Analyses of the Phase 3 VISION Trial of [<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
Kim N Chi, Andrew J Armstrong, Bernd J Krause, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 23, 2024
Prognostic Implications of <sup>68</sup>Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors
Masao Watanabe, Wolfgang P Fendler, Hong Grafe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 11, 2017
<sup>68</sup>Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning
Jeremie Calais, Johannes Czernin, Minsong Cao, et al.
The Lancet. Oncology
|
October 11, 2018
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group
Frédéric E Lecouvet, Daniela E Oprea-Lager, Yan Liu, et al.
Clinical Lung Cancer
|
April 11, 2018
MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy
Henning Reis, Martin Metzenmacher, Moritz Goetz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 14, 2017
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Thomas A Hope, Emily K Bergsland, Murat Fani Bozkurt, et al.
Lancet (London, England)
|
June 8, 2024
[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
Simron Singh, Daniel Halperin, Sten Myrehaug, et al.
Page
of 73